TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05848089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief skills sessions plus EMI skills practice prompts
Description: (1) Three brief treatment sessions delivering core cognitive behavioral therapy (CBT) skills (mindful emotion awareness, cognitive flexibility, and changing emotional behaviors) (during hospitalization), (2) a discretionary booster session to reinforce treatment session content (that may be offered after discharge via either phone or telehealth), and (3) ecological momentary intervention (EMI) prompts to engage in guided skills practice exercises via smartphone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment (EMA)
Description: 4x/day brief smartphone-based EMA surveys assessing negative emotions and STBs

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ecological momentary assessment (EMA)
Description: 4x/day brief smartphone-based EMA surveys assessing negative emotions and STBs

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: TAU (or usual care) during hospitalization and the 28-day post-discharge period

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual (TAU)
Description: TAU (or usual care) during hospitalization and the 28-day post-discharge period
Study: NCT06369545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXERCISE
Description: All participants included in this group will receive Exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EXERCISE
Description: All participants included in this group will receive Exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS
Description: All participants included in this group will receive TENS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ESWT
Description: All participants included in this group will receive ESWT
Study: NCT05356130

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written Educational Material on BLT
Description: Participants in both Arms 2 and 3 will receive written information about how to obtain the greatest BLT benefit, including recommended day/time usage, session duration, eye distance from light box, the length of time to continue using, and the small risk of emergent mania or BD and how to recognize this. Written best practices for ideal BLT will be provided in both Arms 2 and 3 via secure EHR message, email, and/or USPS. PDFs of best practices for BLT will also be available for download on our study website.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written Educational Material on BLT
Description: Participants in both Arms 2 and 3 will receive written information about how to obtain the greatest BLT benefit, including recommended day/time usage, session duration, eye distance from light box, the length of time to continue using, and the small risk of emergent mania or BD and how to recognize this. Written best practices for ideal BLT will be provided in both Arms 2 and 3 via secure EHR message, email, and/or USPS. PDFs of best practices for BLT will also be available for download on our study website.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced BLT Encouragement and Adherence Promotion
Description: BLT phone coaches will follow a four-step approach in engaging with Arm 3 participants: (a) provide encouragement to consider using BLT; (b) provide guidance regarding light box purchase and assist with obtaining compensation for purchase; (c) educate participants about ideal BLT use to obtain maximum benefit; and (d) provide ongoing brief telephonic adherence promotion and motivational interviewing (MI) where warranted to maximize persistent and appropriate BLT use.
Study: NCT05563844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM 11.2 mg/m2
Description: 1 case, Take the medicine once on D1,D 1-21.
Study: NCT05839483

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CXCR4
Description: Participants diagnosed with PA will be asked to be scanned by 68Ga-PentixaFor PET imaging.
Study: NCT04863547

Intervention type: OTHER
Intervention: Data collection
Description: Data collection

Intervention type: OTHER
Intervention: Data collection
Description: Data collection
Study: NCT05189691

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking exercise
Description: Initially starting with 10-15 minutes of physical activity, it will continue until it reaches a duration of 30 or 60 minutes, 3 times a week. The goal is to exceed the previous number of steps each time. If they feel fatigue or palpitations during the day, they can do their exercises the next day. If there are complaints of shortness of breath/shortness of breath, chest pain, palpitation during walking, he should take a break from walking and rest. A pedometer will be used to ensure regular follow-up and control, and the number of steps will be marked on the walking tracking chart. They will be told how to keep a record after each exercise. A weekly phone call will be made to motivate the patient and the researcher will be informed that they can call.
Study: NCT06240754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Provided by BMS.
Study: NCT05521178

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram
Description: ECG to monitor electrical activities of the heart on each visit

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram
Description: ECG to monitor electrical activities of the heart on each visit

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Echocardiogram at baseline and 6 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Echocardiogram at baseline and 6 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac magnetic resonance imaging
Description: Cardiac MRI at baseline and 6 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac magnetic resonance imaging
Description: Cardiac MRI at baseline and 6 months

Intervention type: DEVICE
Intervention: Mobile cardiac telemetry
Description: Mobile cardiac telemetry at baseline and 6 months

Intervention type: DEVICE
Intervention: Mobile cardiac telemetry
Description: Mobile cardiac telemetry at baseline and 6 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood pressure monitoring
Description: Home blood pressure monitoring three times per week

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood pressure monitoring
Description: Home blood pressure monitoring three times per week

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: Blood draw at baseline, 3 and 6 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: Blood draw at baseline, 3 and 6 months
Study: NCT05494619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crovalimab
Description: Crovalimab will be administered at a dose of 1000 milligrams (mg) IV (for participants with body weight ≥ 40 kilograms (kg) and \<100 kg) or 1500 mg IV (for participants with body weight ≥ 100 kg) on Day 1, followed by crovalimab 340 mg SC injections on Days 2, 8, 15 and 22 in all participants.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered IV on Day 1 at a dose of 1000 mg for participants with body weight ≥ 40 kg to \< 100 kg, or 1500 mg for participants with body weight ≥ 100 kg. It will be administered SC on Days 2, 8, 15, and 22 at a dose 340 mg in all participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin therapy
Description: All participants will receive background therapy of IVIg at a dose of 400 milligrams/kilograms (mg/kg) QD for 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous immunoglobulin therapy
Description: All participants will receive background therapy of IVIg at a dose of 400 milligrams/kilograms (mg/kg) QD for 5 days.
Study: NCT05538208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: MMF dosed 600mg/m2 body surface area per dose about every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: MMF dosed twice daily to achieve an area under the concentration-time curve (AUC 0-12h) of MPA \>=60-70 mg\*h/L
Study: NCT06515522

Intervention type: OTHER
Intervention: differential diagnosis
Description: this is a retrospective observational study. no intervention has been or will be performed

Intervention type: OTHER
Intervention: differential diagnosis
Description: this is a retrospective observational study. no intervention has been or will be performed

Intervention type: OTHER
Intervention: differential diagnosis
Description: this is a retrospective observational study. no intervention has been or will be performed
Study: NCT06010732

Intervention type: DRUG
Group type: OTHER
Intervention: 0 ppm F (placebo, negative control)
Description: • Each subject will use this product during one of the three treatment periods in the crossover study design.

Intervention type: DRUG
Group type: OTHER
Intervention: 0 ppm F (placebo, negative control)
Description: • Each subject will use this product during one of the three treatment periods in the crossover study design.

Intervention type: DRUG
Group type: OTHER
Intervention: 0 ppm F (placebo, negative control)
Description: • Each subject will use this product during one of the three treatment periods in the crossover study design.

Intervention type: DRUG
Group type: OTHER
Intervention: 1100 ppm F as sodium fluoride (positive control)
Description: • Each subject will use this product during one of the three treatment periods in the crossover study design.

Intervention type: DRUG
Group type: OTHER
Intervention: 1100 ppm F as sodium fluoride (positive control)
Description: • Each subject will use this product during one of the three treatment periods in the crossover study design.

Intervention type: DRUG
Group type: OTHER
Intervention: 1100 ppm F as sodium fluoride (positive control)
Description: • Each subject will use this product during one of the three treatment periods in the crossover study design.

Intervention type: DRUG
Group type: OTHER
Intervention: 1100 ppm F as sodium fluoride Test Product
Description: • Each subject will use this product during one of the three treatment periods in the crossover study design.

Intervention type: DRUG
Group type: OTHER
Intervention: 1100 ppm F as sodium fluoride Test Product
Description: • Each subject will use this product during one of the three treatment periods in the crossover study design.

Intervention type: DRUG
Group type: OTHER
Intervention: 1100 ppm F as sodium fluoride Test Product
Description: • Each subject will use this product during one of the three treatment periods in the crossover study design.
Study: NCT06202417

Intervention type: DRUG
Intervention: Fruquintinib
Description: an oral tyrosine kinase inhibitor (TKI)

Intervention type: DRUG
Intervention: Fruquintinib
Description: an oral tyrosine kinase inhibitor (TKI)
Study: NCT06634862

Intervention type: OTHER
Group type: OTHER
Intervention: Normatec Air Compression
Description: Intermittent pneumatic pressure has been used in other studies, usually for deep vein thrombosis and vascular disorders. In this way, it has not been compared with other recovery interventions for post-exercise recovery applications.
Study: NCT06054828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHELP@ICU
Description: The 14-day mHELP@ICU consists of the following three components:~1. Cognitive engagement twice daily: Participants will receive orienting communication, plus one of the following training on attention, memory, or function execution.~2. Physical activity once daily: Participants will receive a passive range of motion(ROM) and/or anti-gravity ROM exercise if tolerated.~3. Feeding monitor daily: The exact feeding data will be abstracted from medical records.
Study: NCT05801042

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Placebo product

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Encapsulated Lactocaseibacillus rhamnosus
Description: Probiotic product

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Non-encapsulated Lactocaseibacillus rhamnosus
Description: Probiotic product
Study: NCT05211284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 4 mg
Description: Subjects randomized to Saroglitazar Magnesium 4 mg arm will receive Saroglitazar Magnesium 4 mg treatment until the duration of study (24 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to Placebo arm will receive Placebo treatment until the duration of study (24 weeks).
Study: NCT05687123

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo a blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 Dotatate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo a SSR PET/CT scan
Study: NCT06634862

Intervention type: OTHER
Group type: OTHER
Intervention: Soft Tissue Mobilization
Description: The soft tissue mobilisation technique has been investigated in other studies in terms of its effect on soft tissue and its role recovery. In this way, there is no comparison with other recovery interventions for post-exercise recovery applications.
Study: NCT05371678

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic motor control interventions
Description: Treatment duration will be 8 weeks, two sessions a week. Each session will take approximately 60 minutes. This intervention includes education, dietary advices, core stabilization exercises and pelvic floor muscle training with surface Electromyographic-Biofeedback. In the education will be taught to the child and their parents in the first session. Dietary advices will be given by specialist dietitian. Core stabilization exercises will be performed 2 days a week with a physiotherapist and the session will be approximately 50 minutes. Diaphragmatic breathing will be taught to children in breathing exercises. The pelvic floor muscles exercises will be do by surface Electromyographic-Biofeedback. The Electromyographic-Biofeedback teaches the child how to relax the external anal sphincters with visual and auditory feedback techniques.The child will learn to relax the pelvic floor muscles during defecation by monitoring the recorded electromyographic activity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Treatment duration will be 8 weeks. This intervention includes education, dietary advices and laxative therapy. In the education will be taught to the child and their parents in the first session. Dietary advices will be given by specialist dietitian. Laxative therapy will be adjusted at different doses according to the child's age and weight. Laxative therapy will be administered to children by a specialist doctor.
Study: NCT06634862

Intervention type: OTHER
Group type: OTHER
Intervention: Percussive therapy
Description: Percussive therapy has been investigated in device research and athlete health. In this way, it has not been compared with other recovery interventions for post-exercise recovery applications.
Study: NCT06636422

Intervention type: DRUG
Intervention: Motherwort injection
Description: Patients will be given motherwort injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
Study: NCT05687123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study: NCT06444347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biosynthetic Mesh
Description: The biosynthetic mesh group will undergo hiatal hernia repair with Phasix Mesh (Becton Dickinson, Franklin Lakes, NJ) reinforcement, secured with permanent suture.
Study: NCT05475262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active white noise
Description: Active white noise of 57 dB - 60 dB from 10 pm to 6 am
Study: NCT05318482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational group
Description: In addition to the activities of the usual rehabilitation program, the PT will perform a daily motivational session of 15 minutes in a 1 patient: 1 physiotherapist modality. On that occasion, the patient will report the number of steps performed the previous day; the physiotherapist will check and promote the increase of 10% in the number of steps for the next day. If the patient fails to achieve the goal, the PT will analyze the reasons with the patient, in order to facilitate the achievement of the goal. The PT will advise on the time and place to perform physical activity and the patients will receive a diary to record his/her progress (number of steps and heart rate, Borg Fatigue and Borg Dyspnea before and after an exercise task). The PT will record all these evaluations on an excel database.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: Besides the activities of the usual rehabilitation program, the patients of this group will be provided by the PT only with the generic recommendations of daily exercise during the in-hospital stay
Study: NCT05475262

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive white noise
Description: Sham comparator - white noise machine played at lower decibel level not expected to impact sound level changes
Study: NCT05599321

Intervention type: DIAGNOSTIC_TEST
Intervention: Virtual Navigation System
Description: The Virtual Navigator guidance computer is interfaced to the bronchoscopy hardware to tap off the live bronchoscopy and EBUS video feeds. The standard OR medical team (technicians, clinical fellows, et al.) is on hand, and standard clinical facilities (e.g., fluoroscopy, CT/PET image viewer) are available. Our technical team is also present to record all procedural video and computer display information. It also operates the guidance computer during the guided procedure and offers any assistance in case of unanticipated issues. The participant's clinical bronchoscopy will be recorded by the radiology imaging management system.
Study: NCT05272488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy and vagus nerve stimulation
Description: A neurodinamic intervention of vagus nerve through deep breaths involving diaphragm muscle and manual therapy techniques.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: Manual therapy techniques. Joint manipulation techniques for temporomandibular joints and Soft tissue techniques for the muscles
Study: NCT05010408

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Flavored carbonated soft drink (CSD) at different sweetness levels
Description: Beverage

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Flavored carbonated soft drink (CSD) at different sweetness levels
Description: Beverage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavored carbonated soft drink (CSD) at different sweetness levels
Description: Beverage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavored carbonated soft drink (CSD) at different sweetness levels
Description: Beverage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavored carbonated soft drink (CSD) at different sweetness levels
Description: Beverage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavored carbonated soft drink (CSD) at different sweetness levels
Description: Beverage
Study: NCT06146881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diquafosol sodium 3%
Description: Diquafosol sodium 3% 4 times a day for 4 weeks before cataract surgery and 21 days after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hyaluronate 0.1%
Description: Sodium hyaluronate 0.1% 4 times a day for 4 weeks before cataract surgery and 21 days after surgery
Study: NCT06532591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cadonilimab+paclitaxel/albumin-bound paclitaxel+carboplatin
Description: PD-1/CTLA-4 bispecific antibody，Cadonilimab 10mg/kg IV, q3w, paclitaxel 175mg/m2 or albumin-bound paclitaxel 260mg/m2 ivgtt d1, q3w carboplatin AUC 5 ivgtt d1, q3w
Study: NCT04627571

Intervention type: DRUG
Intervention: Cenegermin Ophthalmic Solution [Oxervate]
Description: An 8-week course of topical cenegermin eye drops given 6 times daily would be started in the affected eye, in conjunction with the pre-existing medical treatment for neurotrophic keratopathy. Patients will be followed-up at 4 weeks, 6 weeks, 8 weeks, 3 months, 6 months, 9 months and 12 months (±2 weeks at each time point) after treatment. At each visit, patients will be assessed to determine the corneal epithelial defect and corneal sensation.
Study: NCT06448247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPY001-001
Description: Experimental

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPY001-001
Description: Experimental

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPY001-001
Description: Experimental

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPY001-001
Description: Experimental

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05421923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR1375 capsules
Description: Ascending single and multiple doses of SR1375 orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ascending single and multiple doses of Placebo orally
Study: NCT06161610

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LITT
Description: The patients in the intervention group will receive LITT, other treatments, including systematic therapy and radiology therapy, would be not restricted except the craniotomy of resection before tumor progression or emergency. The patient is supposed to receive LITT post-randomization within 7 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The patients in the control group will receive the best medical management under guidelines except LITT before tumor progression. Craniotomy will not be restricted,
Study: NCT05268367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy
Description: A brief exposure-based psychotherapy for posttraumatic stress disorder